# Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

> **NCT02635776** · PHASE3 · COMPLETED · sponsor: **Aimmune Therapeutics, Inc.** · enrollment: 555 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **BIOLOGICAL:** AR101 powder provided in capsules & sachets
- **BIOLOGICAL:** Placebo powder provided in capsules & sachets

## Key facts

- **NCT ID:** NCT02635776
- **Lead sponsor:** Aimmune Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2017-12-21
- **Final completion:** 2018-07-02
- **Target enrollment:** 555 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635776, "Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02635776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*